This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n22http://www.rxlist.com/
n6http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n21http://linked.opendata.cz/resource/drugbank/patent/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/property/
n15http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06201/identifier/national-drug-code-directory/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06201
rdf:type
n3:Drug
n3:description
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
n3:dosage
n7:271B49B2-363D-11E5-9242-09173F13E4C5 n7:271B49B3-363D-11E5-9242-09173F13E4C5 n7:271B49B4-363D-11E5-9242-09173F13E4C5 n7:271B49B7-363D-11E5-9242-09173F13E4C5 n7:271B49B5-363D-11E5-9242-09173F13E4C5 n7:271B49B6-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Arroyo S: Rufinamide. Neurotherapeutics. 2007 Jan;4(1):155-62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17199032 # Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW: Rufinamide: a new anti-epileptic medication. Expert Opin Pharmacother. 2007 Aug;8(12):1931-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17696794 # Rufinamide: CGP 33101, E 2080, RUF 331, Xilep. Drugs R D. 2005;6(4):249-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15991887 # Wier HA, Cerna A, So TY: Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. Paediatr Drugs. 2011 Apr 1;13(2):97-106. doi: 10.2165/11586920-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21351809
n3:group
approved
n3:halfLife
Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.
n3:indication
Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.
owl:sameAs
n6:DB06201
dcterms:title
Rufinamide
adms:identifier
n12:62856-582-52 n13:129228 n14:DB06201 n15:D05775 n16:114471 n17:12014051 n18:Rufinamide
n3:mechanismOfAction
Rufinamide is a triazole derivative antiepileptic that prolongs the inactive state of voltage gated sodium channels thus stabilizing membranes, ultimately blocking the spread of partial seizure activity.
n3:patent
n21:6740669
n3:routeOfElimination
Renally (91%; 66% as CGP 47292, 2% as unchanged drug) and fecally (9%) eliminated.
n3:synonym
Xilep Banzel RUF 331
n3:toxicity
The most commonly observed adverse reactions (≥10% and greater than placebo) were headache, dizziness, fatigue, somnolence, and nausea.
n3:volumeOfDistribution
Rufinamide was evenly distributed between erythrocytes and plasma. The apparent volume of distribution is dependent upon dose and varies with body surface area. The apparent volume of distribution was about 50 L at 3200 mg/day. Volume of distribution is similar between adults and children and is non-linear.
n3:foodInteraction
Food increases plasma concentrations of rufinamide and slightly decreases half-life (by 3%)
n3:proteinBinding
26.3% - 34.8% with 90% binding to albumin (27%).
n3:synthesisReference
Emanuele ATTOLINO, Lino COLOMBO, Ilaria MORMINO, Pietro ALLEGRINI, "METHOD FOR THE PREPARATION OF RUFINAMIDE." U.S. Patent US20100234616, issued September 16, 2010.
foaf:page
n20:rufinamide.html n22:banzel-drug.htm
n3:IUPAC-Name
n4:271B49BC-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B49C2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B49C1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B49BE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B49BF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B49C0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B49D2-363D-11E5-9242-09173F13E4C5 n4:271B49BA-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B49D3-363D-11E5-9242-09173F13E4C5 n4:271B49B8-363D-11E5-9242-09173F13E4C5 n4:271B49BB-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B49B9-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:N03AF03
n3:H-Bond-Acceptor-Count
n4:271B49C8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B49C9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B49C3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B49C4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B49C6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B49C5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B49C7-363D-11E5-9242-09173F13E4C5
n3:absorption
The oral suspension and tablet are bioequivalent on a mg per mg basis. Rufinamide is well absorbed but the rate is slow and the extent of absorption decreases as dose is increases. Based on urinary excretion, the extent of absorption was at least 85% following oral administration of a single dose of 600 mg rufinamide tablet under fed conditions. Bioavailability= 70%-85% (decreases with increasing doses); Tmax, fed and fasted states= 4-6 hours; Cmax, 10 mg/kg/day= 4.01 µL/mL; Cmax, 30mg/kg/day= 8.68 µL/mL; AUC (0h-12h), 10mg/kg/day= 37.8±47 µg·h/mL; AUC (0h-12h), 30mg/kg/day= 89.3±59 µg·h/mL.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
106308-44-5
n3:Bioavailability
n4:271B49CE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B49D0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B49D1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B49CD-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B49CC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B49CF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B49BD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B49CA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B49CB-363D-11E5-9242-09173F13E4C5